A354200 Stock Overview
Develops in vitro diagnostics companion diagnostics products and bioinformatics software. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NGeneBio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,655.00 |
| 52 Week High | ₩7,360.00 |
| 52 Week Low | ₩2,180.00 |
| Beta | 1.19 |
| 11 Month Change | -8.45% |
| 3 Month Change | -7.65% |
| 1 Year Change | -48.94% |
| 33 Year Change | -82.30% |
| 5 Year Change | n/a |
| Change since IPO | -89.65% |
Recent News & Updates
Shareholder Returns
| A354200 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 4.7% | -8.1% | 2.9% |
| 1Y | -48.9% | 18.1% | -2.8% |
Return vs Industry: A354200 underperformed the KR Biotechs industry which returned 18.1% over the past year.
Return vs Market: A354200 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
| A354200 volatility | |
|---|---|
| A354200 Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A354200's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A354200's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 102 | Daechul Choi | ngenebio.com |
NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic medical device for human leukocyte antigen typing; and OncoaccuPanel, a solid tumor oncology next generation sequencing test. The company also provides NGeneAnalySys, a software for analysis of the genetic testing data; and EasyHLAanalyzer, which offers the HLA typing identifing human leukocyte antigen for histocompatibility antigens using data from NGS.
NGeneBio Co., Ltd. Fundamentals Summary
| A354200 fundamental statistics | |
|---|---|
| Market cap | ₩36.48b |
| Earnings (TTM) | -₩13.28b |
| Revenue (TTM) | ₩4.99b |
7.3x
P/S Ratio-2.7x
P/E RatioIs A354200 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A354200 income statement (TTM) | |
|---|---|
| Revenue | ₩4.99b |
| Cost of Revenue | ₩3.02b |
| Gross Profit | ₩1.97b |
| Other Expenses | ₩15.26b |
| Earnings | -₩13.28b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -966.93 |
| Gross Margin | 39.56% |
| Net Profit Margin | -266.29% |
| Debt/Equity Ratio | 80.4% |
How did A354200 perform over the long term?
See historical performance and comparison